Primary Health Care & Cancer Prevention Strategies Reviewed By WHO Executive Board 04/02/2020 Grace Ren and Catherine Saez The World Health Organization’s Executive Board tackled two big issues today – primary health care, a cornerstone of WHO’s Universal Health Coverage platform, and cancer, the world’s second leading cause of premature deaths. In a comprehensive report released on World Cancer Day, WHO outlined an action plan that could save 7 million lives from cancer […] Continue reading -> WHO Rolls Out Emergency Action Plan For Member States On Coronavirus 04/02/2020 Elaine Ruth Fletcher A crisis management cell at the United Nations Secretariat level is being created to support global management of the novel coronavirus outbreak, World Health Organization officials said this evening. In a late evening briefing Tuesday to WHO member states attending this week’s 146th Session of the Executive Board, WHO officials laid out their war plan […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> What To Watch At The Executive Board: Emergencies, Universal Health Coverage & Eliminating Cervical Cancer 03/02/2020 Grace Ren and Catherine Saez This week’s Executive Board meeting features a heavy agenda of topics, including a review of progress in WHO’s flagship Universal Health Coverage (UHC) initiative; steps taken to confront the burgeoning coronavirus health emergency; and review of a first-ever WHO strategy to eliminate cervical cancer. Debates over the long-term challenges posed by drug resistant pathogens and […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Rolls Out Emergency Action Plan For Member States On Coronavirus 04/02/2020 Elaine Ruth Fletcher A crisis management cell at the United Nations Secretariat level is being created to support global management of the novel coronavirus outbreak, World Health Organization officials said this evening. In a late evening briefing Tuesday to WHO member states attending this week’s 146th Session of the Executive Board, WHO officials laid out their war plan […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> What To Watch At The Executive Board: Emergencies, Universal Health Coverage & Eliminating Cervical Cancer 03/02/2020 Grace Ren and Catherine Saez This week’s Executive Board meeting features a heavy agenda of topics, including a review of progress in WHO’s flagship Universal Health Coverage (UHC) initiative; steps taken to confront the burgeoning coronavirus health emergency; and review of a first-ever WHO strategy to eliminate cervical cancer. Debates over the long-term challenges posed by drug resistant pathogens and […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> What To Watch At The Executive Board: Emergencies, Universal Health Coverage & Eliminating Cervical Cancer 03/02/2020 Grace Ren and Catherine Saez This week’s Executive Board meeting features a heavy agenda of topics, including a review of progress in WHO’s flagship Universal Health Coverage (UHC) initiative; steps taken to confront the burgeoning coronavirus health emergency; and review of a first-ever WHO strategy to eliminate cervical cancer. Debates over the long-term challenges posed by drug resistant pathogens and […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
What To Watch At The Executive Board: Emergencies, Universal Health Coverage & Eliminating Cervical Cancer 03/02/2020 Grace Ren and Catherine Saez This week’s Executive Board meeting features a heavy agenda of topics, including a review of progress in WHO’s flagship Universal Health Coverage (UHC) initiative; steps taken to confront the burgeoning coronavirus health emergency; and review of a first-ever WHO strategy to eliminate cervical cancer. Debates over the long-term challenges posed by drug resistant pathogens and […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> Posts navigation Older postsNewer posts